Cancer Genetics Again Lowers Expected Proceeds from IPO to $23.5M | GenomeWeb

NEW YORK (GenomeWeb News) – Cancer Genetics has again lowered the amount it expects to bring in from its pending initial public offering, the Rutherford, NJ-based firm disclosed in a document filed with the US Securities and Exchange Commission late on Wednesday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: map of UV-induced damage in yeast genome, comparative epigenomics uncovers plant lacking key DNA methyltransferase enzyme, and more.

Researchers kick off their second Queer in STEM survey to examine what can make STEM careers welcoming, Wired reports.

A startup company is offering a test to analyze soil samples from farms for pathogens.

Prosecutors seek to introduce evidence from low-template DNA analysis in a murder case in upstate New York, the New York Times reports.